Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRMT1v2 siRNA is a small interfering RNA (siRNA) designed to specifically target and deplete the PRMT1v2 isoform, an alternatively spliced, predominantly cytoplasmic variant of protein arginine methyltransferase 1 (PRMT1). PRMT1v2 is overexpressed in breast cancer cell lines and tumors, where it promotes cell survival, growth, and invasiveness. Depletion of PRMT1v2 using this siRNA induces apoptosis and significantly reduces the invasive capacity of aggressive breast cancer cells, such as MDA-MB-231, by restoring levels of the cell-cell adhesion protein β-catenin. It is primarily utilized as a research tool to study isoform-specific functions of PRMT1 in oncology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PRMT1v2 siRNA.